Kenvue Inc. $KVUE Shares Sold by DAVENPORT & Co LLC

DAVENPORT & Co LLC cut its stake in Kenvue Inc. (NYSE:KVUE) by 80.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,838 shares of the company’s stock after selling 165,769 shares during the quarter. DAVENPORT & Co LLC’s holdings in Kenvue were worth $687,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. American Century Companies Inc. grew its stake in shares of Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after buying an additional 6,781,640 shares in the last quarter. Independent Franchise Partners LLP raised its holdings in shares of Kenvue by 233.4% during the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock valued at $654,388,000 after buying an additional 21,886,537 shares during the period. Dimensional Fund Advisors LP lifted its position in Kenvue by 13.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock worth $375,377,000 after acquiring an additional 2,747,952 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Kenvue by 101.3% in the 3rd quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock worth $298,008,000 after acquiring an additional 9,240,434 shares during the period. Finally, Invesco Ltd. grew its position in Kenvue by 11.0% in the second quarter. Invesco Ltd. now owns 17,818,771 shares of the company’s stock valued at $372,947,000 after acquiring an additional 1,759,065 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $17.22 on Tuesday. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a market cap of $33.00 billion, a P/E ratio of 22.36, a price-to-earnings-growth ratio of 3.98 and a beta of 0.51. The stock has a 50 day moving average of $18.01 and a 200-day moving average of $17.11.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. The business had revenue of $3.78 billion during the quarter, compared to analyst estimates of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.26 earnings per share. On average, analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s payout ratio is presently 107.79%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Barclays upped their target price on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Friday, March 6th. Citigroup lifted their price target on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. UBS Group boosted their price objective on shares of Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. Finally, Jefferies Financial Group cut shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $23.00 to $18.00 in a research report on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat, Kenvue has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.